已知恶性肿瘤患者FDG PET/CT上无CT对应灶的局灶性肝摄取:MRI评估的价值
回顾性分析1851例已知恶性肿瘤患者中36例FDG PET/CT见局灶性肝摄取但CT无对应灶且100天内行MRI者,共50个摄取部位;MRI确认26个(52%)有对应病灶,其中20个(77%)证实为转移,占全部50个部位的40%;有无MRI对应灶及良恶性组间SUVmax及SUVmax比值均无统计学显著差异。
要点
- PET/CT上无CT对应灶的局灶性肝摄取中约40%为转移瘤,值得进一步MRI评估。
- MRI有对应病灶的肝摄取中77%证实为转移。
- SUVmax及病灶/背景比值不能区分有无MRI对应灶及良恶性。
核心结论
- 本研究中超过半数无CT对应灶的局灶性肝摄取在MRI上有对应病灶,其中超过75%为转移瘤,与SUVmax无关。
研究设计与样本
- 回顾性研究,2005至2012年间从1851例已知恶性肿瘤患者中识别36例(女19例、男17例,平均年龄56.1岁)FDG PET/CT见局灶性肝摄取但CT无对应灶且100天内行MRI评估者;两名放射科医师共同阅片达成共识,测量病灶及背景肝SUVmax,以随访影像和病理数据确认或排除转移。
关键影像表现/征象
- 共识别50个无CT对应灶的局灶性肝摄取部位。
- MRI在50个部位中确认26个(52%)有对应病灶。
诊断标准与关键数值
- 肝病灶SUVmax中位数4.1(范围2.1-10.1),病灶与正常肝实质SUVmax比值中位数1.3(范围0.98-2.6)。
- 有MRI对应灶组与无MRI对应灶组肝病灶SUVmax中位数3.85 vs 4.2(p=0.5),SUVmax比值1.32 vs 1.31(p=0.97),均无统计学显著差异。
- 最终诊断为良性病变组与转移组SUVmax 4.05 vs 3.95(p=0.64),SUVmax比值1.31 vs 1.32(p=0.91),均无统计学显著差异。
临床应用与阅片要点
- 对PET/CT上无CT对应灶的局灶性肝摄取应行MRI进一步评估,因其中约40%为转移瘤。
- SUVmax及SUVmax比值不能用于区分有无MRI对应病灶或良恶性,阅片时不应据此判断。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study was to determine the significance and utility of MRI in evaluation of focal hepatic uptake on FDG PET/CT without a CT correlate in patients with known malignancy. MATERIALS AND METHODS. In this retrospective study, we identified 36 of 1851 patients between 2005 and 2012 with known malignancy (19 women, 17 men; mean age, 56.1 years old) who had focal hepatic uptake on FDG PET/CT without a CT correlate and follow-up MRI within 100 days for assessment of uptake. Two radiologists reviewed the FDG PET/CT images together, reached consensus about presence of focal hepatic uptake, and measured maximum standardized uptake value (SUVmax) of the focal uptake and background liver. MR images were then reviewed to identify any correlate. Follow-up imaging and histopathologic data were reviewed to confirm or refute metastasis. Statistical correlation between intensity of FDG uptake and presence of focal lesions on MRI was performed. RESULTS. Fifty sites of focal hepatic uptake without CT correlate were identified. The median SUVmax was 4.1 (range, 2.1-10.1), whereas the ratio of median SUVmax of the hepatic lesion to that of normal parenchyma was 1.3 (range, 0.98-2.6). MRI confirmed focal lesions in 26 of 50 sites (52%). Seventy-seven percent of cases of hepatic uptake with an MRI correlate (20/26) were confirmed as metastatic disease (six cases at histopathology). Therefore, 40% of cases of hepatic uptake without a CT correlate (20/50) were metastases. We found no statistically significant difference in the SUVmax of hepatic lesions and SUVmax ratio between the groups with and without an MRI correlate (median SUVmax = 3.85 vs 4.2, p = 0.5; SUVmax ratio = 1.32 vs 1.31, p = 0.97) as well as between the groups with the final diagnosis of benign lesions and metastasis (SUVmax = 4.05 vs 3.95, p = 0.64; SUVmax ratio = 1.31 vs 1.32, p = 0.91). CONCLUSION. More than half of the cases of focal hepatic uptake on PET/CT without a CT correlate had an MRI correlate in our study, and more than 75% of these lesions were metastases, regardless of SUVmax.
引用
- Araki T, Mouhieddine TH, Tirumani SH, et al. Focal Liver Uptake on FDG PET/CT Without CT Correlate: Utility of MRI in the Evaluation of Patients With Known Malignancy. AJR Am J Roentgenol. 2019. PMID: 30995099. doi:10.2214/AJR.18.21035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。